利培酮联合帕罗西汀治疗慢性精神分裂症阴性症状

Paroxetine combined risperidone in the treatment of negative symptoms of chronic schizophrenia patients

目的:探讨利培酮联合帕罗西汀治疗慢性精神分裂症阴性症状的临床疗效以及安全性。方法:将126例以阴性症状为主的慢性精神分裂症住院患者随机分为研究组(利培酮联合帕罗西汀治疗)和对照组(单用利培酮治疗),疗程12周,采用阳性和阴性症状量表(PANSS)和治疗中出现的症状量表(TESS)评定疗效和安全性。结果:治疗后两组PANSS评分均较治疗前有显著降低(P<0.05)。治疗后4、8、12周末,研究组阴性因子分及情感迟钝、情感退缩、情感交流障碍及社会退缩因子分均显著低于对照组,差异具有统计学意义(P<0.05或P<0.01)。两组不良反应均为轻至中度。结论:利培酮联合帕罗西汀较单用利培酮治疗慢性精神分裂症阴性症状具有起效更快、疗效更好、依从性好的特点。

Objective：To evaluate clinical efficacy and safety of paroxetine combined risperidone in the treatment of negative symptoms of chronic schizophrenia patients.Method：126 patients with predominantly negative symptoms of chronic schizophrenia were randomly divided into study group （paroxetine combined risperidone） and the control group （risperidone alone） with 12 weeks＇ treatment.PANSS and TESS were used to assess the efficacy and safety respectively.Results：compared with before treatment,PANSS scores decreased significantly after treatment （P0.05）.The scores on b1unted affect,emotional withdrawal,poor rapport and passive/apathetic social withdrawal were lower in the study group than in the control group at week 4,8 and 12,the score difference was statistically significant （P0.05 or P0.01）.The adverse events of two groups were mild or moderate.Conclusion：Paroxetine combined risperidone in the treatment of chronic schizophrenia with negative symptoms showed rapid response,better efficacy and good patient compliance.